期刊
BIOMEDICINE & PHARMACOTHERAPY
卷 146, 期 -, 页码 -出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2021.112572
关键词
Interferon-beta; Treatment; COVID-19; SARS-CoV-2; Mortality
资金
- Fundacion SEIMC/GeSIDA [COVID-19/SEIMC-FSG]
- Plan Nacional de I+D+i 2013-2016
- Instituto de Salud Carlos III
- Subdireccion General de Redes y Centros de Investigacion Cooperativa
- Ministerio de Ciencia, Innovacion y Universidades
- European Development Regional Fund A way to achieve Europe from the CIBER de Enfermedades Infecciosas (CIBERINFEC) [RD16CIII/0002/0006, RD16/0025/0017, RD16/0025/0018, RD16/0016/0001, RD16/0016/0005, RD16/0016/0009, CB21/13/00091, CB21/13/00044, CB21/13/00039, CB21/13/00012, CB21/13/00009]
- European Development Regional Fund
In this multicenter cohort of admitted COVID-19 patients, receiving early interferon-beta therapy after hospital admission did not show an association with lower mortality. Whether interferon-beta might be useful in the earlier stages of the disease or specific subgroups of patients requires further research.
Background: Interferon-p is an attractive drug for repurposing and use in the treatment of COVID-19, based on its in vitro antiviral activity and the encouraging results from clinical trials. The aim of this study was to analyze the impact of early interferon-p treatment in patients admitted with COVID-19 during the first wave of the pandemic. Methods: This post hoc analysis of a COVID-19@Spain multicenter cohort included 3808 consecutive adult patients hospitalized with COVID-19 from 1 January to 17 March 2020. The primary endpoint was 30-day all-cause mortality, and the main exposure of interest was subcutaneous administration of interferon-beta, defined as early if started <= 3 days from admission. Multivariate logistic and Cox regression analyses were conducted to identify the associations of different variables with receiving early interferon-beta therapy and to assess its impact on 30-day mortality. A propensity score was calculated and used to both control for confounders and perform a matched cohort analysis. Results: Overall, 683 patients (17.9%) received early interferon-p therapy. These patients were more severely ill. Adjusted HR for mortality with early interferon-p was 1.03 (95% CI, 0.82-1.30) in the overall cohort, 0.96 (0.82-1.13) in the PS-matched subcohort, and 0.89 (0.60-1.32) when interferon-beta treatment was analyzed as a time-dependent variable. Conclusions: In this multicenter cohort of admitted COVID-19 patients, receiving early interferon-beta therapy after hospital admission did not show an association with lower mortality. Whether interferon-beta might be useful in the earlier stages of the disease or specific subgroups of patients requires further research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据